Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

- PMLiVE

Lilly revenues down as generics erode Zyprexa sales

Sales of antipsychotic drug fall 68 per cent during third quarter

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

- PMLiVE

Diabetes care recognised at UK awards

Joint working between pharma, NHS and patient organisations key among winners at QiC Diabetes 2012

- PMLiVE

NICE and ABPI clash over access to medicines

Trade body says research shows medicines underused but NICE claims new figures 'higher than expected'

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

- PMLiVE

Patient access schemes likely to remain under VBP, says NICE

New and existing schemes expected to have place within UK’s new pricing environment

- PMLiVE

Independent analysis raises hope for Lilly’s Alzheimer’s drug

Pooled results show solanezumab slowed cognitive decline in subgroup by 34 per cent

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links